<DOC>
	<DOCNO>NCT00264173</DOCNO>
	<brief_summary>Primary Objective : - To compare efficacy valproate lithium Bipolar I patient suffer manic mixed episode accord DSM IV TR ( APA 2000 ) [ Diagnostic Statistical Manual Mental Disorders ( DSM ) fourth edition ( IV ) Text Revision ( TR ) ] periode 3 week 12 week treatment Secondary Objective : - To evaluate clinical biological safety valproate compare lithium .</brief_summary>
	<brief_title>VALID : VAlproate Versus LIthium Bipolar Disorders</brief_title>
	<detailed_description />
	<mesh_term>Bipolar Disorder</mesh_term>
	<mesh_term>Valproic Acid</mesh_term>
	<criteria>The following information clinical trial provide information purpose allow patient physician initial discussion trial . This information intend complete information trial , contain consideration may relevant potential participation trial , replace advice personal physician health professional . Main criterion list hereafter : Inclusion criterion Screening : Patients history least one manic episode previous three year age 60 patient old 60 screening , document medical record , relative 's report information corroborate evidence manic symptomatology patient already know bipolar patient . Newly diagnose patient bipolar disorder allow provide diagnosis base DSM IV TR [ Diagnostic Statistical Manual Mental Disorders ( DSM ) fourth edition ( IV ) Text Revision ( TR ) ] patient le 30 year old . Patients current diagnosis Bipolar I Disorder accord DSM IV TR Patients suffer current manic episode mixed episode accord DSM IV TR Patients minimum total score Young Mania Rating Scale ( YMRS ) 18 Screening Inclusion criterion D0 ( Day 0 ) : Patients complete washout period least 1 day duration ( except patient receive psychiatric treatment benzodiazepine dose low equivalence 8 mg lorazepam except patient receive injectable longacting neuroleptic least 7 day prior Screening ) Patients minimum total score Young Mania Rating Scale ( YMRS ) 18 D0 Exclusion criterion Screening : Participation clinical trial within three previous month Patients history valproate intolerance define valproate discontinuation due medically significant adverse effect Patients history lithium intolerance define lithium discontinuation due medically significant adverse effect Patients Central Nervous System ( CNS ) neoplasm , demyelinate disease , degenerative neurological disorder , active CNS infection progressive disorder may blur interpretation study result Patients history seizure disorder , cerebrovascular disease , structural brain damage trauma , clinically significant focal neurological abnormality , know EEG ( Electroencephalography ) frank paroxysmal activity know CT scan brain demonstrating gross structural abnormality Patients uncontrolled gastrointestinal , renal , hepatic , endocrine , cardiovascular , pulmonary , immunological hematological disease Patients renal insufficiency , cardiac insufficiency Addison 's disease Patients past current pancreatitis Patients acute hepatitis , chronic hepatitis , family history severe hepatitis especially drug relate , hepatic porphyry Patients current DSM IV diagnosis alcohol substance dependence ( exception nicotine caffeine dependence ) substance abuse stimulant include limited cocaine , heroin , crack , amphetamine , pseudoephedrine , cold medication phenylephrine stimulant . Alcohol marijuana abuse prior study entry accept related current manic episode , base investigator 's judgment Pregnancy lactation . Women child bear age therefore use reliable contraceptive method Patients require 300 mg aspirin per day Patients medical condition require continuous use treatment could interfere safety efficacy evaluation valproate ( anticonvulsant anticoagulant therapy , zidovudine ) lithium ( angiotensin convert enzyme inhibitor , tetracycline , reserpine , calcium channel blocker , triptans ) Patients receive injectable longacting neuroleptic less 7 day prior Screening Patients necessitate Electro Convulsive Therapy Congenital prolongation QT interval Exclusion criterion D0 : Patients treat antidepressant within 5 day prior randomization ( D0 ) fluoxetine within 20 day precede D0 Patients alteration laboratory test potential significance : ASAT ALAT &gt; 3 ULN ( Upper Limit Normal ) Alkaline phosphatase level &gt; 1.5 ULN Serum creatinine &gt; = 150 Âµmol/l Hemoglobin &lt; 12 g/dl ( men ) &lt; 11 g/dl ( woman ) Platelets &lt; 150 000 /mm3 Neutrophils &lt; 1 500 /mm3 Prothrombin time &lt; 75 % TSH ( ThyroidStimulating Hormone ) normal range QTc Bazett &gt; 450 m male &gt; 470 ms female ECG ( Electrocardiogram ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>November 2007</verification_date>
</DOC>